Amneal Pharmaceuticals, based in Bridgewater, New Jersey, has voluntarily recalled 13 lots of Lorazepam Oral Concentrate, USP 2mg/mL, Lorazepam Oral Concentrate, USP 2mg/mL — a product for which the accompanying dropper dispenser may be erroneously labeled. Read More »
Naloxone, a nasal spray developed as an antidote for opioid overdose, will soon become available to Pennsylvania first responders thanks to support and outreach efforts sponsored by Philadelphia-based managed care provider AmeriHealth Caritas. Read More »
Walgreens recently announced the launch of its Center for Health & Wellbeing Research, a website documenting roughly 50 outcomes from studies the company undertook in the past six years. Read More »
Regeneron Pharmaceuticals Inc. recently announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), failed to meet its primary endpoint. Read More »
Arcadia Biosciences Inc., an agricultural technology company, recently received FDA approval from the U.S. Food and Drug Administration for the use of its safflower oil in dog diets. Read More »
Apollo Endosurgery Inc. recently announced an update and clarifications to a letter sent by the U.S. Food and Drug Administration to health care providers about potential risks with liquid-filled intragastric balloons. Read More »
Soligenix Inc., a late-stage biopharmaceutical company that creates rare-disease targeting products, recently announced that its good manufacturing practices-compliant bulk drug substance, RiVax, has received funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Read More »
Arcadia Biosciences Inc. and Bioceres S.A. have entered a joint venture titled Verdeca, and announced that the company’s safety evaluation for HB4 soybeans received a full review by the U.S. Food and Drug Administration. Read More »
Sweden’s research-oriented pharmaceutical firm Medivir AB's Investigational New Drug application for an osteoarthritis treatment has been accepted by, and is currently open with, the U.S. Food and Drug Administration. Read More »
The U.S. Food and Drug Administration advises consumers and health care professionals to not use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands. Read More »
The international market for insulin delivery devices remains highly competitive with at least six major producers currently dominating the trade, according to Transparency Market Research, which predicts continued growth over the next eight years. Read More »
Ionis Pharmaceuticals Inc. will retain all rights to inotersen and IONIS-FB-LRx. Read More »
Diplomat Pharmacy Inc. recently announced that it will dispense opioid-overdose antidote naloxone without prescription to residents in Michigan via the company’s retail pharmacy at G-3320 Beecher Road in Flint. Read More »
Having disputed portions of Novartis’ patent for Gilenya (fingolimod), an immunosuppressant used to treat MS, New York City-based Argentum Pharmaceuticals LLC successfully obtained a special petition from the U.S. Patent & Trademark Office (PTO) recently. Read More »
A resubmitted Biologics License Application from California-based Portola Pharmaceuticals was recently deemed acceptable for review by the U.S. Food and Drug Administration and assigned an expected action due date of Feb. 2, 2018. Read More »
Takeda Pharmaceuticals Co. Limited recently announced that it will collaborate with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM) to transform novel Stanford research into next-generation treatments for diseases. Read More »
After a comprehensive review, CVS Pharmacy has retained Community Pharmacy Accreditation from industry benchmark organization Utilization Review Accreditation Commission. Read More »
To improve access to medical treatment for far-flung Kansas residents, UnitedHealthcare Community Plan of Kansas recently presented several regional health care facilities with its Frontier Rural Health Care grants, ranging from $45,000 to $48,000 each. Read More »
Jerusalem-based Teva Pharmaceutical Industries Ltd. recently began marketing generic Axiron (testosterone) topical solution CIII, 30 mg/1.5 mL, in the United States for treating adult males who are experiencing low testosterone levels due to medical reasons. Read More »
An innovative treatment for certain types of acute lymphoblastic leukemia (ALL).1 — Pfizer’s Besponsa (inotuzumab ozogamicin) — recently obtained approval from the U.S. Food and Drug Administration via its Breakthrough Therapy designation and Priority Review programs. Read More »
Alerts Sign-up
